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An analysis ofsurveillance for stage I combined teratoma -seminoma ofthe
testis
R Thomas, D Dearnaley, J Nicholls, A Norman, S Sampson and A Horwich
Academic Urology Unit, The Royal Marsden NHS Trust, Downs Road, StUtton, Surrey SM2 SPT, UK.
Summary We analysed 973 patients with stage I testicular tumours presenting between 1983 and 1994. The
median ages at presentation for non-seminomatous germ cell tumour (teratoma) were 27 years, seminoma 36
years and combined tumour 33 years. These differences were statistically significant (Mann-Whitney P<0.05),
suggesting that combined tumours may have a separate natural history. We, therefore, analysed all stage I
patients managed with surveillance (530 in total) post orchidectomy. The actuarial 5 year relapse-free survival
and anatomical patterns of relapse were identical for non-seminomatous germ cell tumour (NSGCT) and
combined tumour and both were statistically distinct from seminoma (P=0.01, log-rank test, chi-square test
P=0.001). The association of seminoma within a histologically confirmed NSGCT has no influence on the
clinical outcome.
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The conventional management of patients with stage I
seminoma of the testis is distinct from those with stage I
non-seminomatous germ cell tumour (NSGCT). For semi-
noma this is by adjuvant retroperitoneal lymph node
irradiation. This policy is highly successful, recurrences
occur in less than 5% of patients (Hamilton et al., 1986;
Zagars, 1991) and long-term morbidity is low (Horwich and
Bell, 1994; Hamilton et al., 1987). Surveillance has been
investigated (Duchesne et al., 1990; Horwich et al., 1992;
Oliver et al., 1994; Von der Maase et al., 1993; Thomas et al.,
1989) but a number of clinical difficulties have become
apparent: the relative indolent natural history of seminoma
leading to a requirement for prolonged surveillance; the lack
of a sensitive serum marker (Mason, 1991) for seminoma,
making it difficult to monitor patients sufficiently closely to
detect small volume relapse; and, finally, the lack of verified
prognostic factors for relapse, making it difficult to predict
the higher risk patients (Horwich et al., 1992; Von der Maase
et al., 1993). In contrast surveillance is a more attractive
option in the management of stage I NSGCT and is the
conventional management for patients in the UK (Horwich,
1993; Cullen, 1991). Clear prognostic factors for relapse exist
(Freedman et al., 1987; Read et al., 1992). Follow-up is
easier: sensitive tumour markers are available in over 60% of
cases (Mason 1991). Over 90% of relapses occur within the
first year (Freedman et al., 1987; Read et al., 1992) making
prolonged intensive follow-up unnecessary.
A substantial minority of patients present with a
combination of both seminoma and NSGCT in the post-
orchidectomy specimen (Horwich, 1991). In these patients, it
has not been established from the literature which component
exerts the strongest influence on clinical outcome. In this
study we have assessed a large cohort of patients with stage I
disease comparing presenting features and outcome following
surveillance for patients with combined tumour, NSGCT and
seminoma.
Materials and methods
A total of 973 patients with stage 1 testicular tumours were
referred to the Royal Marsden NHS Trust (RMNHST)
between 1983 and 1994. Investigations used to confirm
RMNHST stage I (Peckham, 1971) disease included the
following: chest radiography; computerised tomography of
the chest, abdomen and pelvis; full blood count and
biochemistry; and serum alpha-fetoprotein (AFP) and beta
human chorionic gonadotrophin (HCG). All histological
specimens were reviewed to confirm the diagnosis of either
pure seminoma, pure NSGCT-classified according to the
British Testicular Tumour Panel (Pugh and Cameron, 1976)
or combined germ cell tumours. Combined tumours were
defined as those containing both teratomatous and semi-
nomatous tumour (Horwich, 1991; Pugh and Cameron, 1976;
Ray, 1974) (Figure 1). All relevant clinicopathological data
were recorded prospectively on a dedicated computer data
base. This included the MRC prognostic risk factors for
relapse: vascular and lymphatic invasion, lack of yolk sac
elements and the presence of undifferentiated elements
(Freedman et al., 1987; Read and Stenning, 1992). In this
cohort of patients the incidence and age at presentation of
the three histological groups were analysed.
A total of 320 patients with seminoma were treated with
adjuvant radiotherapy and 123 patients with NSGCT treated
with adjuvant chemotherapy. The remaining 530 patients
were managed with surveillance post orchidectomy. A total
of 292 (55%) had pure NSGCT, 121 (23%) had combined
tumours and 117 (22%) had pure seminoma (Duchesne et al.,
1990; Horwich et al., 1992). The eligibility criteria for patients
with seminoma treated with surveillance or adjuvant radio-
therapy was identical (Duchesne et al., 1990; Cullen, 1991).
Furthermore, assessment of the MRC histological risk factors
showed that tumour characteristics for all patients managed
by surveillance were similar to those treated by immediate
adjuvant chemotherapy or radiation (Table I). This shows
that there was no selection bias between the three groups and
that patients managed by surveillance are representative of
the entire patient population.
Statistical considerations
The age at presentation within the three histological groups
was analysed by the Mann-Whitney test. The incidence of
prognostic factors for relapse and the patterns of disease at
relapse were analysed by the chi-square test. The relapse-free
survival was measured from the date of orchidectomy and
analysed by the log-rank method (Peto et al., 1977).
Results
Pure seminoma was present in 45% (437 patients) of the
entire cohort, pure NSGCT 41% (402 patients) and
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Figure 1 Histological features of a combined germ cell tumour
(H&E x 109). Top left, malignant teratoma undifferentiated
(MTU). Bottom right, classical seminoma. The teratoma consists
of islands of large pleomorphic undifferentiated cells with a
carcinomatous appearance. The seminoma has sheets of smaller
cells with clear cytoplasm and central nuclei admixed with
lymphocytes.
combined tumours 14% (134 patients). The median age at
presentation for NSGCT was 27 years, combined tumours 33
years and seminoma 36 years (Figure 2). There was a
statistical age difference between each of these groups
(Mann -Whitney P<0.05). Likewise, in the surveillance
only patients age at presentation was statistically distinct
between the three groups (27 years, 32 years and 37 years
respectively).
For the groups of patients managed by surveillance, the
actuarial 5 year relapse-free survival was 69.5% NSGCT,
71% combined tumours and 84% seminoma (Figure 3).
There was no statistical difference between the combined
tumour and NSGCT groups (P=0.5, log-rank test) but a
strong difference with combined tumour vs seminoma
(P=0.006) and NSGCT vs seminoma (P=0.005). Analysis
of the time distribution of relapse demonstrated similar
patterns for NSGCT and combined tumours and both were
distinctly different from seminoma (Figure 3). For the
NSGCT and combined tumour patients who relapsed (or
were censored) within 5 years, a significantly greater
proportion relapsed from 0-1 years than 1-2 or 2-5 years
(NSGCT 81%, 9% and 10%; combined tumours 74%, 12%,
14%). In contrast, for seminoma the relapses were spread
evenly over 5 years (0-1 years 38%, 1-2 years 28%, 2-5
years 34%). The anatomical pattern of relapse was also
similar for the combined tumour and NSGCT groups (Table
II and Figure 4) (chi-square test P=0.65). There was a
significant difference between the combined tumours and pure
seminoma (chi-square test P=0.001) as well as between the
NSGCT and seminoma groups (chi-square test P=0.001).
For example, over 90% of patients with seminoma relapsed
in the abdominal nodes alone compared with 47% NSGCT
and 46% combined tumours (chi-square test P=0.001).
::40
30
-a20
10
Teratoma Cognbin4d. Seminoma
Figure 2 Median ages at presentation of 973 patients with stage
I testicular tumours for three histological groups teratoma-
NSGST. l-l, ±2 s.d.
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Figure 3 Percentage relapse-free survival of three histological
groups of stage I testicular tumours managed with surveillance
(teratoma =NSGCT).
Discussion
Our study shows that the median age at presentation for
patients with stage I testicular germ cell tumour of the three
histological subgroups was distinctly different. This agrees
with the findings of previous authors (Pugh and Cameron,
1976). Patients with combined tumours (33 years) were closer
in age to those with seminoma (36 years) than those with
Table I The incidence of MRC prognosis factors for relapse from Freedman et al. (1987) and Read et al. (1992)
MRC prognosticfactors Vascular invasion Lymphatic invasion Lack of Yolk sac Undifferentiated elements
Histological type T C S T C S T C S T C S
All stage I patients (%) 33 30 31 12 12 18 32 36 - 36 41
Surveillance patients (%) 30 28 30 10 11 17 31 34 - 34 39
Statistical difference NS NS NS NS
T, pure NSGCT; C, combined NSGCT and seminoma; S, seminoma. NS, non-significant (chi2-square p<0.05).
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Table I Stage at relapse
No. of
Histological patients Stage at relapse (%)
type relapsed Stage II Stage III Stage IV
NSGCT 91 43 (47%) 8 (9%) 40 (44%)
Combined 34 15 (46%) 3 (8%) 16 (46%)
Seminona 18 17 (92%) 0 (0%) 1 (8%)
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F*_e 4 Anatomical sites of relapse in 530 stage I patients on
surveiLlance (Royal Marsden staging, teratoma=NSGCI).
NSGCT (27 years). The clinical significance of this
phenomenon is small as patients in all three groups
commonly present at ages between 27 and 36 years
(Horwich, 1991) and age is not a prognostic indicator for
relapse (Horwich et al., 1992; Von der Maase et al., 1993;
Freedman et al., 1987; Read et al., 1992). It does, however,
suggest a possible distinct disease entity that may have
resulted-in a unique clinical outcome for each group. The
conventional management for seminoma and NSGCT are
currently different in our (Horwich, 1993; Duchesne et al.,
1990; Horwich et al., 1992) and other institutions (Cullen,
1991; Oliver et al., 1994; Von der Maase et al., 1993; Thomas
et al., 1989). This study was, therefore, necessary to establish
which element within combined tumours exerts the strongest
influence on clinical outcome. By doing so, the most
appropriate management pathway for patients with histolo-
gically defined combined tumours could be determined.
Our analysis demonstrated that despite these different ages
at presentation, patients with combined tumours behaved in a
similar manner to those with pure NSGCT: the 5 year
relapse-free survival was the same (69.5% and 71%); the time
pattern of relapse was the same-most patients relapsed in
the first year rather than spread over the first 5 years as in
seminoma (Figure 3), the anatomical pattern of relapse was
identical-92% of seminomas occurred within the para-aortic
nodes as opposed to 47% NSGCT and 46% combined
tumours (Figure 4).
This study confirms the clinical impression among
experienced clinicians (Horwich, 1993; Cullen, 1991; Hoeltl
et al., 1992). The association of seminoma within a
histologically confirmed NSGCT has no influence on the
clinical outcome of patients managed with surveillance post
orchidectomy. Patients with histologically combined stage I
testicular germ cell tumours should be managed with the
same intent as those with pure NSGCT.
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